HRP20210516T2 - Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr - Google Patents
Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr Download PDFInfo
- Publication number
- HRP20210516T2 HRP20210516T2 HRP20210516TT HRP20210516T HRP20210516T2 HR P20210516 T2 HRP20210516 T2 HR P20210516T2 HR P20210516T T HRP20210516T T HR P20210516TT HR P20210516 T HRP20210516 T HR P20210516T HR P20210516 T2 HRP20210516 T2 HR P20210516T2
- Authority
- HR
- Croatia
- Prior art keywords
- degrees
- analytical technology
- compound
- tablet
- process analytical
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 35
- 101150029409 CFTR gene Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000011057 process analytical technology Methods 0.000 claims 21
- 229940125904 compound 1 Drugs 0.000 claims 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 230000005855 radiation Effects 0.000 claims 12
- 238000012544 monitoring process Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 238000004497 NIR spectroscopy Methods 0.000 claims 5
- 239000008187 granular material Substances 0.000 claims 5
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 4
- 238000012360 testing method Methods 0.000 claims 4
- 238000001069 Raman spectroscopy Methods 0.000 claims 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 229940125782 compound 2 Drugs 0.000 claims 2
- 238000009826 distribution Methods 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 238000005469 granulation Methods 0.000 claims 2
- 230000003179 granulation Effects 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 238000012023 real time release testing Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000007962 solid dispersion Substances 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 238000010924 continuous production Methods 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000011049 filling Methods 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- -1 humidity Substances 0.000 claims 1
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- UFSKUSARDNFIRC-UHFFFAOYSA-N lumacaftor Chemical group N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/44—Raman spectrometry; Scattering spectrometry ; Fluorescence spectrometry
- G01J3/4406—Fluorescence spectrometry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Pulmonology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (34)
1. Kontinuirani postupak za proizvodnju tablete, naznačen time, da tableta sadrži Spoj 1 (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeva kiselina) Oblik I i čvrstu disperziju koja sadrži bitno amorfan Spoj 2 (N-(5-hidroksi-2,4-diterc-butil-fenil)-4-okso-1H-kinolin-3-karboksamid), s time, da postupak obuhvaća sljedeće korake:
(a) miješanje u miješalici Spoja 1 Oblika I, čvrste disperzije koja sadrži u osnovi amorfan Spoj 2, punilo i dezintegrator, kako bi se dobila smjesa;
(b) priprava granulacijske otopine s vodom, vezivom i tenzidom;
(c) punjenje smjese iz koraka a) u kontinuirani dvostruki vijčani granulator i u isto vrijeme dodavanje granulacijske otopine iz koraka b), u svrhu proizvodnje granula;
(d) sušenje granula iz koraka c) i njihovo mljevenje;
(e) miješanje mljevenih granula iz koraka d) s punilom, dezintegratorom i mazivom, kako bi se dobila smjesa; i
(f) stlačivanje smjese iz koraka e) u tabletu;
pri čemu najmanje jedan od gore spomenutih koraka obuhvaća procesnu analitičku tehnologiju.
2. Postupak prema patentnom zahtjevu 1, naznačen time, da korak a) obuhvaća procesnu analitičku tehnologiju, pri čemu procesna analitička tehnologija jest NIR spektroskopija za nadgledanje ujednačenosti smjese.
3. Postupak prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da korak b) obuhvaća procesnu analitičku tehnologiju.
4. Postupak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da korak c) obuhvaća procesnu analitičku tehnologiju.
5. Postupak prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da korak d) obuhvaća procesnu analitičku tehnologiju, pri čemu procesna analitička tehnologija jest NIR spektroskopija za nadgledanje ujednačenosti granula i/ili za nadgledanje sadržaja vlage, ili gdje procesna analitička tehnologija jest laserska difrakcija za nadgledanje raspodjele veličine čestica.
6. Postupak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da korak e) obuhvaća procesnu analitičku tehnologiju, pri čemu procesna analitička tehnologija jest NIR spektroskopija za nadgledanje ujednačenosti smjese.
7. Postupak prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da korak e) obuhvaća procesnu analitičku tehnologiju, pri čemu procesna analitička tehnologija jest NIR spektroskopija za nadgledanje sadržaja vlage.
8. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da korak f) obuhvaća procesnu analitičku tehnologiju, pri čemu procesna analitička tehnologija jest Ramanova spektroskopija za nadgledanje identičnosti čvrstog oblika djelatnog farmaceutskog sastojka.
9. Postupak prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da korak f) obuhvaća procesnu analitičku tehnologiju, gdje procesna analitička tehnologija jest ispitivanje tablete za nadgledanje težine tablete.
10. Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da korak f) obuhvaća procesnu analitičku tehnologiju, gdje procesna analitička tehnologija jest ispitivanje tablete za nadgledanje debljine tablete.
11. Postupak prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da korak f) obuhvaća procesnu analitičku tehnologiju, gdje procesna analitička tehnologija jest ispitivanje tablete za nadgledanje čvrstoće tablete.
12. Postupak prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da postupak obuhvaća oblaganje tablete, i nadgledanje debljine obloge putem tehnika Ramanove spektroskopije.
13. Postupak prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time, da procesna analitička tehnologija obuhvaća barem jednu od laserske difrakcije, ispitivanja tablete, tehnika NIR i Ramanove spektroskopije, u svrhu nadgledanja definiranih standarda.
14. Postupak prema patentnom zahtjevu 13, naznačen time, da se definirani standard odabire od ujednačenosti smjese, ujednačenosti granula, vlažnosti, raspodjele veličine čestica, identičnosti čvrstog oblika djelatnog farmaceutskog sastojka, koncentracije djelatnog farmaceutskog sastojka, težine, debljine, čvrstoće i debljine obloge.
15. Postupak prema patentnom zahtjevu 13 ili 14, naznačen time, da se definirani standard nadgleda radi ispitivanja otpuštanja u stvarnom vremenu (engl. real time release testing – RTRT).
16. Postupak prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da je Oblik I karakteriziran kao kristalni oblik koji posjeduje monoklinski kristalni sustav, prostornu skupinu P21/n i sljedeće dimenzije jedinične ćelije:
a = 4,9626 (7) Å
b = 12,299 (2) Å β = 93,938 (9)°
c = 33,075 (4) Å, i/ili
pri čemu je Oblik I naznačen time, da posjeduje jedan ili više maksimuma na 15,4 ± 0,2 stupnjeva, 16,3 ± 0,2 stupnjeva, i 14,5 ± 0,2 stupnjeva pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
17. Postupak prema patentnom zahtjevu 16, naznačen time, da je Spoj 1 Oblik I naznačen time, da posjeduje jedan ili više maksimuma unutar jednog ili više raspona vrijednosti 2θ, koji su odabrani od 15,2 do 15,6 stupnjeva, 16,1 do 16,5 stupnjeva i 14,3 do 14,7 stupnjeva pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
18. Postupak prema patentnom zahtjevu 17, naznačen time, da je Spoj 1 Oblik I naznačen time, da posjeduje maksimum koji ima vrijednost 2θ na 15,2 do 15,6 stupnjeva pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
19. Postupak prema patentnom zahtjevu 18, naznačen time, da je Spoj 1 Oblik I naznačen time, da posjeduje maksimum koji ima vrijednost 2θ na 15,4 stupnjeva pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
20. Postupak prema patentnom zahtjevu 17, naznačen time, da je Spoj 1 Oblik I naznačen time, da posjeduje maksimum koji ima vrijednost 2θ na 16,1 do 16,5 stupnjeva pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
21. Postupak prema patentnom zahtjevu 20, naznačen time, da je Spoj 1 Oblik I naznačen time, da posjeduje maksimum koji ima vrijednost 2θ na 16,3 stupnjeva pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
22. Postupak prema patentnom zahtjevu 17, naznačen time, da je Spoj 1 Oblik I naznačen time, da posjeduje maksimum koji ima vrijednost 2θ na 14,3 do 14,7 stupnjeva pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
23. Postupak prema patentnom zahtjevu 22, naznačen time, da je Spoj 1 Oblik I naznačen time, da posjeduje maksimum koji ima vrijednost 2θ na 14,5 stupnjeva pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
24. Postupak prema patentnom zahtjevu 17, naznačen time, da je Spoj 1 Oblik I nadalje naznačen time, da posjeduje maksimum koji ima vrijednost 2θ na 17,6 do 18,0 stupnjeva pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
25. Postupak prema patentnom zahtjevu 17, naznačen time, da je Spoj 1 Oblik I nadalje naznačen time, da posjeduje maksimum koji ima vrijednost 2θ na 7,6 do 8,0 stupnjeva pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
26. Postupak prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da je Spoj 1 Oblik I naznačen time, da posjeduje najmanje jedan maksimum koji ima vrijednost 2θ, ± 0,2 stupnja, koja je odabrana od 14,41 stupnjeva; 14,64 stupnjeva; 15,23 stupnjeva; 16,11 stupnjeva; 17,67 stupnjeva; 19,32 stupnjeva; 21,67 stupnjeva; 23,40 stupnjeva; 23,99 stupnjeva; 26,10 stupnjeva; i 28,54 stupnjeva; pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
27. Postupak prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da je Spoj 1 Oblik I naznačen time, da posjeduje najmanje jedan maksimum koji ima vrijednost 2θ, ± 0,2 stupnja, koja je odabrana od 7,83 stupnjeva; 14,51 stupnjeva; 14,78 stupnjeva; 15,39 stupnjeva; 16,26 stupnjeva; 16,62 stupnjeva; 17,81 stupnjeva; 21,59 stupnjeva; 23,32 stupnjeva; 24,93 stupnjeva; i 25,99 stupnjeva pri rendgenskoj difrakciji na prahu dobivenoj uporabom CuKα radijacije.
28. Postupak prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da je Spoj 1 Oblik I naznačen time, da posjeduje difrakcijski uzorak prema Slici 1.
29. Postupak prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da je Spoj 1 Oblik I naznačen time, da posjeduje difrakcijski uzorak prema Slici 2.
30. Postupak prema patentnom zahtjevu 16, naznačen time, da je Spoj 1 Oblik I karakteriziran kao monoklinski kristalni sustav i prostorna skupina P21/n, te posjeduje sljedeće dimenzije jedinične ćelije:
a = 4,9626 (7) Å
b = 12,299 (2) Å β = 93,938 (9)°
c = 33,075 (4) Å.
31. Tableta, naznačena time, da se proizvodi putem postupka prema bilo kojem od patentnih zahtjeva 1 do 30.
32. Tableta prema patentnom zahtjevu 31, naznačena time, da je za uporabu u liječenju cistične fibroze kod pacijenta.
33. Tableta za uporabu prema patentnom zahtjevu 32, naznačena time, da pacijent ima mutaciju ΔF508 u CFTR.
34. Tableta za uporabu prema patentnom zahtjevu 33, naznačena time, da pacijent jest homozigot za mutaciju ΔF508 u CFTR.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361903010P | 2013-11-12 | 2013-11-12 | |
US201461929604P | 2014-01-21 | 2014-01-21 | |
US201462000659P | 2014-05-20 | 2014-05-20 | |
EP14862504.9A EP3068392B9 (en) | 2013-11-12 | 2014-10-31 | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
PCT/US2014/063506 WO2015073231A1 (en) | 2013-11-12 | 2014-10-31 | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20210516T1 HRP20210516T1 (hr) | 2021-05-14 |
HRP20210516T2 true HRP20210516T2 (hr) | 2021-10-01 |
Family
ID=53057872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210516TT HRP20210516T2 (hr) | 2013-11-12 | 2021-03-30 | Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr |
Country Status (23)
Country | Link |
---|---|
US (1) | US10231932B2 (hr) |
EP (1) | EP3068392B9 (hr) |
JP (2) | JP6963896B2 (hr) |
KR (1) | KR102280372B1 (hr) |
CN (1) | CN105848657B (hr) |
AU (1) | AU2014349010C1 (hr) |
BR (1) | BR112016010403A2 (hr) |
CA (1) | CA2930199C (hr) |
DK (1) | DK3068392T5 (hr) |
ES (1) | ES2865600T3 (hr) |
HR (1) | HRP20210516T2 (hr) |
HU (1) | HUE054389T2 (hr) |
IL (2) | IL245584A0 (hr) |
MX (1) | MX2016006118A (hr) |
NZ (1) | NZ720958A (hr) |
PL (1) | PL3068392T3 (hr) |
PT (1) | PT3068392T (hr) |
RS (1) | RS61790B1 (hr) |
RU (2) | RU2718044C2 (hr) |
SG (1) | SG10201803930QA (hr) |
SI (1) | SI3068392T1 (hr) |
WO (1) | WO2015073231A1 (hr) |
ZA (1) | ZA201603973B (hr) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
WO2006002421A2 (en) | 2004-06-24 | 2006-01-05 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
KR101331768B1 (ko) | 2005-11-08 | 2013-11-22 | 버텍스 파마슈티칼스 인코포레이티드 | Atp 결합 카세트 수송체의 헤테로사이클릭 조정제 |
ES2624554T3 (es) | 2005-12-28 | 2017-07-14 | Vertex Pharmaceuticals Incorporated | Formas sólidas de n- [2,4 - bis (1,1 - dimetiletil) - 5 - hidroxifenil] - 1,4 - dihidro - 4 - oxoquinolina - 3 - carboxamida |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
NZ571803A (en) | 2006-04-07 | 2011-12-22 | Vertex Pharma | Amide indole derivatives as modulators of ATP-binding cassette transporters |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
CN102917692A (zh) | 2010-04-07 | 2013-02-06 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法 |
CA2797118C (en) | 2010-04-22 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
US20130186801A1 (en) * | 2012-01-25 | 2013-07-25 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
WO2014014841A1 (en) | 2012-07-16 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
EP3131582B1 (en) | 2014-04-15 | 2018-05-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
CN107690281B (zh) | 2014-10-06 | 2020-11-17 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
US10653622B1 (en) * | 2015-04-13 | 2020-05-19 | Pharmacoustics Technologies LLC | Individualized solid dosage products and a system and method for the globally integrated pharmaceutical manufacturing and its monitoring thereof |
US20180250232A1 (en) * | 2015-09-03 | 2018-09-06 | Merck Sharp & Dohme Corp. | Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations |
WO2017170858A1 (ja) | 2016-03-31 | 2017-10-05 | 大日本住友製薬株式会社 | 溶出性に優れた経口製剤 |
US10383865B2 (en) | 2016-04-25 | 2019-08-20 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
HUP1600271A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei |
US10206915B2 (en) | 2016-04-25 | 2019-02-19 | Druggability Technologies Ip Holdco Limited | Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
HUP1600269A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei |
HUP1600270A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei |
US10376501B2 (en) | 2016-04-25 | 2019-08-13 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
WO2018037350A1 (en) * | 2016-08-23 | 2018-03-01 | Laurus Labs Limited | Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof |
DK3519401T3 (da) | 2016-09-30 | 2021-11-22 | Vertex Pharma | Modulator af cystisk fibrosetransmembrankonduktansregulator, farmaceutiske sammensætninger, fremgangsmåder til behandling og fremgangsmåde til fremstilling af modulatoren |
IL294237A (en) | 2016-12-09 | 2022-08-01 | Vertex Pharma | Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator |
AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
CA3069226A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AR112467A1 (es) | 2017-08-02 | 2019-10-30 | Vertex Pharma | Procesos para preparar compuestos |
JP7175966B2 (ja) * | 2017-08-31 | 2022-11-21 | ノバルティス アーゲー | 顆粒剤を調製する方法 |
IL273831B1 (en) | 2017-10-19 | 2024-06-01 | Vertex Pharma | Crystal forms and preparations of CFTR modulators |
JP7245834B2 (ja) | 2017-12-08 | 2023-03-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス |
EP3746078A4 (en) * | 2018-02-02 | 2021-11-17 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | ORAL FORMULATIONS AND USES THEREOF |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
MD3752510T2 (ro) | 2018-02-15 | 2023-06-30 | Vertex Pharma | Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora |
WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
CN114599657A (zh) | 2019-08-14 | 2022-06-07 | 弗特克斯药品有限公司 | Cftr调节剂的结晶形式 |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
EP3818975A1 (en) * | 2019-11-08 | 2021-05-12 | Roquette Freres | Use of sodium octenyl-succinate starches as a binder in continuous wet granulation |
US20230372247A1 (en) * | 2022-05-17 | 2023-11-23 | Sigachi Industries Limited | Self-disintegrating excipient composition for solid oral dosage forms |
Family Cites Families (237)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3758475A (en) | 1971-07-20 | 1973-09-11 | Sandoz Ag | Pyrido(2,3-d)pyrimidin 2 ones |
DE3263567D1 (en) | 1981-12-14 | 1985-06-20 | Medea Res Srl | New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions |
IT1226048B (it) | 1981-12-14 | 1990-12-10 | Medea Res Srl | Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative |
US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
US5981714A (en) | 1990-03-05 | 1999-11-09 | Genzyme Corporation | Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor |
JP3167762B2 (ja) | 1990-11-27 | 2001-05-21 | 武田薬品工業株式会社 | ピリドピリダジン誘導体およびその用途 |
US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
CA2107196A1 (en) | 1992-09-29 | 1994-03-30 | Mitsubishi Chemical Corporation | Carboxamide derivatives |
GB9317764D0 (en) | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
WO1995011231A1 (en) | 1993-10-21 | 1995-04-27 | G. D. Searle & Co. | Amidino derivatives useful as nitric oxide synthase inhibitors |
DE4405712A1 (de) | 1994-02-23 | 1995-08-24 | Basf Ag | Substituierte Naphthyridine und deren Verwendung |
IL113313A (en) | 1994-04-11 | 1999-09-22 | Sankyo Co | Heterocyclic compounds and pharmaceutical compositions containing the same |
CN1068880C (zh) | 1994-09-27 | 2001-07-25 | 詹森药业有限公司 | N-取代的哌啶基双环苯甲酸酯衍生物 |
US5656256A (en) | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
US5510379A (en) | 1994-12-19 | 1996-04-23 | Warner-Lambert Company | Sulfonate ACAT inhibitors |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
CA2249615A1 (en) | 1996-04-03 | 1997-10-09 | Robert Gomez | Inhibitors of farnesyl-protein transferase |
DK0984778T3 (da) | 1996-08-23 | 2002-09-16 | Agouron Pharma | Neuropeptid-Y-ligander |
CA2276081A1 (en) | 1996-12-30 | 1998-07-09 | Lekhanh O. Tran | Inhibitors of farnesyl-protein transferase |
CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
US5948814A (en) | 1997-02-20 | 1999-09-07 | The Curators Of The University Of Missouri | Genistein for the treatment of cystic fibrosis |
WO1998047868A1 (en) | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists |
IL135177A0 (en) | 1997-10-02 | 2001-05-20 | Sankyo Co | Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same |
US6277626B1 (en) | 1998-02-17 | 2001-08-21 | G.D. Searle & Co. | Process for the enzymatic resolution of lactams |
AR019626A1 (es) | 1998-06-08 | 2002-02-27 | Schering Corp | Antagonistas receptores y5 de neuropeptidos. |
US6426331B1 (en) | 1998-07-08 | 2002-07-30 | Tularik Inc. | Inhibitors of STAT function |
AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
US6444686B1 (en) | 1998-12-18 | 2002-09-03 | Brsitol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
RU2236402C2 (ru) | 1999-02-24 | 2004-09-20 | Ф.Хоффманн-Ля Рош Аг | Производные 3-фенилпиридина и фармацевтическая композиция на их основе |
ES2226622T3 (es) | 1999-02-24 | 2005-04-01 | F. Hoffmann-La Roche Ag | Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1. |
CA2364665C (en) | 1999-02-24 | 2009-09-15 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives |
GB2347739A (en) * | 1999-03-09 | 2000-09-13 | Pfizer Ltd | Powder Analysis |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
BR0012291A (pt) | 1999-06-18 | 2002-03-26 | Bayer Ag | Fenoxifluorpirimidinas |
UA74539C2 (en) | 1999-12-08 | 2006-01-16 | Pharmacia Corp | Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants) |
WO2001046165A2 (en) | 1999-12-16 | 2001-06-28 | Novartis Ag | N-heteroaryl-amides and their use as parasiticides |
WO2001051919A2 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
AU2001233069A1 (en) | 2000-01-28 | 2001-08-07 | Biogen, Inc. | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses |
US20020065303A1 (en) | 2000-02-01 | 2002-05-30 | Bing-Yan Zhu | Bivalent phenylene inhibitors of factor Xa |
US20010047100A1 (en) | 2000-04-26 | 2001-11-29 | Kjaersgaard Hans Joergen | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
WO2001083517A1 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Stat4 and stat6 binding dipeptide derivatives |
US6499984B1 (en) | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
EP1268450A1 (en) | 2000-06-01 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Lactams substituted by cyclic succinates as inhibitors of a-beta protein production |
TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
PE20020451A1 (es) | 2000-09-15 | 2002-06-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de cinasa proteina |
JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
AU2002211379A1 (en) | 2000-10-04 | 2002-04-15 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of cystic fibrosis |
GB2367816A (en) | 2000-10-09 | 2002-04-17 | Bayer Ag | Urea- and thiourea-containing derivatives of beta-amino acids |
DE60104014T2 (de) | 2000-10-20 | 2005-08-11 | Merck Patent Gmbh | Chirale binaphtol-verbindungen |
US6884782B2 (en) | 2000-11-08 | 2005-04-26 | Amgen Inc. | STAT modulators |
CA2430363C (en) | 2000-12-01 | 2010-04-13 | Guilford Pharmaceuticals Inc. | Compounds and their uses |
GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US6531597B2 (en) | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
JP2005520171A (ja) | 2001-04-10 | 2005-07-07 | トランス テック ファーマ,インコーポレイテッド | ドラッグディスカバリーに関する、プローブ、システム、および方法 |
PT1385577E (pt) | 2001-04-23 | 2006-08-31 | Hoffmann La Roche | Utilizacao de antagonistas do receptor nk-1 contra a hiperplasia prostatica benigna |
SK15432003A3 (sk) | 2001-05-22 | 2004-05-04 | Neurogen Corporation | 5-Substituované 2-arylpyridíny |
US20030083345A1 (en) | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
WO2003007945A1 (en) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US20030144350A1 (en) | 2001-07-20 | 2003-07-31 | Adipogenix, Inc. | Fat accumulation-modulation compounds |
JP2005508904A (ja) | 2001-09-11 | 2005-04-07 | スミスクライン ビーチャム コーポレーション | 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体 |
PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
JP2003221386A (ja) | 2001-11-26 | 2003-08-05 | Takeda Chem Ind Ltd | 二環性誘導体、その製造法およびその用途 |
PL370989A1 (en) | 2001-12-21 | 2005-06-13 | Novo Nordisk A/S | Amide derivatives as gk activators |
TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
JP2005535710A (ja) | 2002-08-09 | 2005-11-24 | トランス テック ファーマ,インコーポレイテッド | アリールおよびヘテロアリール化合物ならびに凝固を調節する方法 |
GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
JP3546208B2 (ja) * | 2002-10-02 | 2004-07-21 | 明治製菓株式会社 | 経口吸収性が改善された抗菌性医薬組成物 |
AU2003287160A1 (en) | 2002-10-15 | 2004-05-04 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
US7514431B2 (en) | 2002-10-30 | 2009-04-07 | Merck & Co., Inc. | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity |
US7910030B2 (en) | 2002-11-26 | 2011-03-22 | Universiteit Gent | Process and apparatus for continuous wet granulation of powder material |
EP1569645A2 (en) | 2002-12-12 | 2005-09-07 | Pharmacia Corporation | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
SI1585739T1 (sl) | 2003-01-06 | 2011-07-29 | Lilly Co Eli | Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze |
NZ542153A (en) | 2003-02-10 | 2009-01-31 | Vertex Pharma | Processes for the preparation of N-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
WO2004080972A1 (en) | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
US7358364B2 (en) | 2003-04-30 | 2008-04-15 | The Institute For Pharmaceutical Discovery Llc | Substituted carboxylic acids |
ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
ATE554766T1 (de) | 2003-06-27 | 2012-05-15 | Jackson H M Found Military Med | Amphiphile pyridinium-verbindungen, herstellungsverfahren und ihre verwendung |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
JP2005053902A (ja) | 2003-07-18 | 2005-03-03 | Nippon Nohyaku Co Ltd | フェニルピリジン類、その中間体及びこれを有効成分とする除草剤 |
EA200600372A1 (ru) | 2003-09-05 | 2006-08-25 | Ньюроджин Корпорейшн | Конденсированные с гетероарилом пиридины, пиразины и пиримидины в качестве лигандов рецептора кортикотропин-рилизинг-фактора (crf 1) |
US7973169B2 (en) | 2003-09-06 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
MXPA06004005A (es) | 2003-10-08 | 2006-06-28 | Vertex Pharma | Moduladores de transportadores con casete de union con atp. |
US20070078120A1 (en) | 2003-10-21 | 2007-04-05 | Hitoshi Ban | Novel piperidine derivative |
FR2861304B1 (fr) | 2003-10-23 | 2008-07-18 | Univ Grenoble 1 | Modulateurs des canaux cftr |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
ATE437640T1 (de) | 2003-11-14 | 2009-08-15 | Vertex Pharma | Thiazole udn oxazole als modulatoren von atp- bindungs-kassetten-transportern |
EP1687001A2 (en) | 2003-11-19 | 2006-08-09 | Glaxo Group Limited | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders |
ES2238001B1 (es) | 2004-01-21 | 2006-11-01 | Vita Cientifica, S.L. | Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos. |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
WO2005075435A1 (en) | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
EP1719765A4 (en) | 2004-02-19 | 2009-01-07 | Banyu Pharma Co Ltd | NEW SULFONAMIDE DERIVATIVE |
JP5168711B2 (ja) * | 2004-03-25 | 2013-03-27 | アステラス製薬株式会社 | ソリフェナシンまたはその塩の固形製剤用組成物 |
ES2241496B1 (es) | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
US20080015196A1 (en) | 2004-04-16 | 2008-01-17 | Neurogen Corporation | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands |
EP1740575A2 (en) | 2004-04-22 | 2007-01-10 | Eli Lilly And Company | Pyrrolidine derivatives useful as bace inhibitors |
US7585885B2 (en) | 2004-04-22 | 2009-09-08 | Eli Lilly And Company | Pyrrolidine derivatives useful as BACE inhibitors |
AU2005249154B2 (en) | 2004-06-01 | 2011-02-10 | Luminex Molecular Diagnostics, Inc. | Method of detecting cystic fibrosis associated mutations |
TWI356036B (en) * | 2004-06-09 | 2012-01-11 | Smithkline Beecham Corp | Apparatus and method for pharmaceutical production |
US20140343098A1 (en) | 2004-06-24 | 2014-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
WO2006002421A2 (en) | 2004-06-24 | 2006-01-05 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
WO2006003504A1 (en) | 2004-07-01 | 2006-01-12 | Warner-Lambert Company Llc | Preparation of pharmaceutical compositions containing nanoparticles |
CA2572292A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
WO2006014012A2 (en) | 2004-08-06 | 2006-02-09 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds |
US20060069110A1 (en) | 2004-09-27 | 2006-03-30 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
ES2378772T3 (es) | 2004-10-12 | 2012-04-17 | Astrazeneca Ab | Derivados de quinazolina |
JP2008519818A (ja) | 2004-11-15 | 2008-06-12 | ファイザー・プロダクツ・インク | Cns障害の治療のためのアザベンゾオキサゾール |
SI1856031T1 (sl) | 2004-12-15 | 2009-08-31 | Dompe Pha R Ma Spa Res & Mfg | Derivati 2-arilpropionske kisline in farmacevtski sestavki, ki jih vsebujejo |
JP4790260B2 (ja) | 2004-12-22 | 2011-10-12 | 出光興産株式会社 | アントラセン誘導体を用いた有機エレクトロルミネッセンス素子 |
US20080146612A1 (en) | 2005-01-27 | 2008-06-19 | Astrazeneca Ab | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor |
US7888374B2 (en) | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
EP1845081A4 (en) | 2005-02-01 | 2009-03-25 | Takeda Pharmaceutical | amide |
JP5385605B2 (ja) | 2005-03-11 | 2014-01-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atp結合カセットトランスポーターのモジュレーター |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
TWI377206B (en) | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
TW200716594A (en) | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
US20090215780A1 (en) | 2005-04-19 | 2009-08-27 | Bayer Pharmaceuticals Corporation | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity |
JP2008538561A (ja) | 2005-04-20 | 2008-10-30 | メルク エンド カムパニー インコーポレーテッド | アンジオテンシンii受容体アンタゴニスト |
MX2007013179A (es) | 2005-04-22 | 2008-01-16 | Wyeth Corp | Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina. |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
US8822451B2 (en) | 2005-05-24 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
JP2008545744A (ja) | 2005-06-02 | 2008-12-18 | バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト | フェニルアルキル置換ヘテロアリール誘導体 |
EP1919875A2 (en) | 2005-06-21 | 2008-05-14 | Astex Therapeutics Limited | Pyrazole derivatives and their use as pka and pkb modulators |
CA2618057A1 (en) | 2005-08-11 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
ZA200802172B (en) | 2005-08-11 | 2009-06-24 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
EP2336136A1 (en) | 2005-09-09 | 2011-06-22 | GlaxoSmithKline LLC | Pyridine derivatives and their use in the treatment of psychotic disorders |
ES2335922T3 (es) | 2005-09-23 | 2010-04-06 | F.Hoffmann-La Roche Ag | Nueva formulacion de dosificacion. |
CA2624683A1 (en) | 2005-10-06 | 2007-04-19 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
CA2625189A1 (en) | 2005-10-19 | 2007-04-26 | Gruenenthal Gmbh | Novel vanilloid receptor ligands and their use for producing medicaments |
US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
KR101331768B1 (ko) | 2005-11-08 | 2013-11-22 | 버텍스 파마슈티칼스 인코포레이티드 | Atp 결합 카세트 수송체의 헤테로사이클릭 조정제 |
WO2007054480A1 (en) | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
GB0606891D0 (en) * | 2006-04-05 | 2006-05-17 | Council Cent Lab Res Councils | Raman Analysis Of Pharmaceutical Tablets |
EP1971606B1 (en) | 2005-12-05 | 2013-04-24 | GlaxoSmithKline LLC | 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors |
CA2634113A1 (en) | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of abc transporters |
AU2006331565A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in CFTR assays and methods therewith |
ES2624554T3 (es) | 2005-12-28 | 2017-07-14 | Vertex Pharmaceuticals Incorporated | Formas sólidas de n- [2,4 - bis (1,1 - dimetiletil) - 5 - hidroxifenil] - 1,4 - dihidro - 4 - oxoquinolina - 3 - carboxamida |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
ES2398319T3 (es) | 2005-12-28 | 2013-03-15 | Vertex Pharmaceuticals Incorporated | Derivados de 1-(benzo[D][1,3]dioxol-5-il)-N-(fenil)ciclopropano-carboxamida y compuestos relacionados como moduladores de transportadores de casetes de unión a ATP para el tratamiento de la fibrosis quística |
WO2007079257A2 (en) | 2005-12-30 | 2007-07-12 | Caliper Life Sciences, Inc. | Integrated dissolution processing and sample transfer system |
NZ571803A (en) | 2006-04-07 | 2011-12-22 | Vertex Pharma | Amide indole derivatives as modulators of ATP-binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
AU2007249269A1 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide |
EP2026787B1 (en) * | 2006-05-13 | 2013-12-25 | Novo Nordisk A/S | Tablet formulation comprising repaglinide and metformin |
AU2007351454B2 (en) | 2006-11-03 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
MX2009005622A (es) | 2006-11-27 | 2009-06-12 | Novartis Ag | Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores. |
JP2008183168A (ja) * | 2007-01-30 | 2008-08-14 | Ebara Corp | 錠剤製造システム |
US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
AU2008247435A1 (en) | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | Combination therapy with a compound acting as a platelet ADP receptor inhibitor |
WO2008141119A2 (en) | 2007-05-09 | 2008-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
ES2548292T3 (es) | 2007-05-25 | 2015-10-15 | Vertex Pharmaceuticals Incorporated | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
WO2009023509A2 (en) | 2007-08-09 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Therapeutic combinations useful in treating cftr related diseases |
JP5389030B2 (ja) | 2007-08-24 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | (特に)嚢胞性線維症の処置に有用なイソチアゾロピリジノン |
DE102007042754A1 (de) | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
CN101821266B (zh) | 2007-09-14 | 2014-03-12 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
BRPI0816345A2 (pt) | 2007-09-14 | 2015-02-24 | Vertex Pharma | Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida |
FR2921657A1 (fr) | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
JP5646338B2 (ja) | 2007-11-16 | 2014-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atp結合カセットトランスポーターのイソキノリン調節因子 |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
UA102534C2 (en) | 2007-12-07 | 2013-07-25 | Вертекс Фармасьютикалз Инкорпорейтед | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]-dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
SI2639224T1 (sl) | 2007-12-07 | 2016-12-30 | Vertex Pharmaceuticals Incorporated | Postopek za pripravo cikloalkilkarboksiamido-piridinskih benzojskih kislin |
WO2009076141A2 (en) | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
AU2008335031B2 (en) | 2007-12-13 | 2013-11-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
KR20100113602A (ko) * | 2008-02-05 | 2010-10-21 | 하버 바이오사이언시즈 인코포레이티드 | 고체 형태의 약제 |
EP2271622B1 (en) | 2008-02-28 | 2017-10-04 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as CFTR Modulators |
ES2442945T3 (es) | 2008-03-31 | 2014-02-14 | Vertex Pharmaceuticals Inc. | Derivados de piridilo como moduladores del CFTR |
GB0813709D0 (en) | 2008-07-26 | 2008-09-03 | Univ Dundee | Method and product |
KR20240066199A (ko) | 2008-08-13 | 2024-05-14 | 버텍스 파마슈티칼스 인코포레이티드 | 제약 조성물 및 그의 투여 |
US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
RU2011117177A (ru) | 2008-09-29 | 2012-11-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | ДОЗИРОВАННЫЕ ЛЕКАРСТВЕННЫЕ ФОРМЫ 3-(6-(1-(2,2-ДИФТОРБЕНЗО[d][1,3]ДИОКСОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ |
US20110257223A1 (en) | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
US8314239B2 (en) | 2008-10-23 | 2012-11-20 | Vertex Pharmaceutical Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
DK2358680T3 (da) | 2008-10-23 | 2013-06-24 | Vertex Pharma | Faste former af n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluormethyl)phenyl)-3-oxo-5-(trifluormethyl)-1,4-dihydroquinolin-3-carboxamid |
NZ592685A (en) | 2008-10-23 | 2013-04-26 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
KR20160013251A (ko) | 2008-11-06 | 2016-02-03 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송자의 조절자 |
EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
DK2408749T3 (en) | 2009-03-20 | 2018-08-13 | Vertex Pharma | CYSTIC FIBROSE TRANSMEMBRAN CONDUCTOR CONTROLLER MODULATORS |
CA2756031C (en) | 2009-03-20 | 2018-01-02 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
WO2010114638A1 (en) * | 2009-03-30 | 2010-10-07 | E. I. Du Pont De Nemours And Company | Peptide-based tooth whitening reagents |
CN102438578A (zh) * | 2009-05-07 | 2012-05-02 | 基伊埃制药系统有限公司 | 药片生产模块和用于连续生产药片的方法 |
JP5355269B2 (ja) * | 2009-07-16 | 2013-11-27 | 大日本住友製薬株式会社 | 顕微ラマン分光法による固体材料中の分散粒子の粒径の測定法 |
MX2012003343A (es) | 2009-09-17 | 2012-08-17 | Vertex Pharma | Proceso para preparar compuestos azabiciclicos. |
CA2777245A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
BR112012009583A2 (pt) | 2009-10-23 | 2015-09-29 | Vertex Pharma | processo para preparação de moduladores de regulador de condutância de transmembrana de fibrose cística |
NZ599703A (en) | 2009-10-23 | 2014-06-27 | Vertex Pharma | Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
US8471029B2 (en) | 2010-03-19 | 2013-06-25 | Vertex Pharmaceutical Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
NZ700556A (en) | 2010-03-25 | 2016-04-29 | Vertex Pharma | Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide |
EP2555754B1 (en) | 2010-04-07 | 2016-04-06 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
CN102917692A (zh) | 2010-04-07 | 2013-02-06 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法 |
EP2560650A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
CA2797118C (en) | 2010-04-22 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
EP3138563A1 (en) | 2010-04-22 | 2017-03-08 | Vertex Pharmaceuticals Inc. | Pharmaceutical compositions and administrations thereof |
AU2011242457A1 (en) | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
TW201202250A (en) | 2010-05-20 | 2012-01-16 | Vertex Pharma | Processes for producing modulators of cystic fibrosis transmembrane conductance regulator |
CA2798412A1 (en) | 2010-05-20 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
JP2013536231A (ja) | 2010-08-23 | 2013-09-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | (r)−1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)−n−(1−(2,3−ジヒドロキシプロピル)−6−フルオロ−2−(1−ヒドロキシ−2−メチルプロパン−2−イル)−1h−インドール−5−イル)シクロプロパンカルボキサミドを含む医薬組成物およびその投与 |
WO2012027731A2 (en) | 2010-08-27 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
CN102058889A (zh) | 2010-11-05 | 2011-05-18 | 王定豪 | 包含抗凝血类药物的分散片及其应用 |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
WO2012148953A1 (en) * | 2011-04-25 | 2012-11-01 | Stc.Unm | Solid compositions for pharmaceutical use |
JP5798400B2 (ja) * | 2011-07-26 | 2015-10-21 | 富士電機株式会社 | 医薬品製造制御装置、医薬品製造制御方法、医薬品製造制御プログラム、医薬品製造システム |
EP2773349A1 (en) | 2011-11-02 | 2014-09-10 | Vertex Pharmaceuticals Incorporated | Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases |
US20140127901A1 (en) | 2012-11-08 | 2014-05-08 | Taiwan Semiconductor Manufacturing Company, Ltd. | Low-k damage free integration scheme for copper interconnects |
US9254291B2 (en) | 2011-11-08 | 2016-02-09 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US20130186801A1 (en) | 2012-01-25 | 2013-07-25 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
EP2659890A1 (en) * | 2012-04-30 | 2013-11-06 | Orphan Synergy Europe - Pharma | Methods and compositions for the treatment of fibrosis |
WO2013185112A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
WO2014014841A1 (en) | 2012-07-16 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
US20140092376A1 (en) | 2012-10-01 | 2014-04-03 | Momentive Performance Materials, Inc. | Container and method for in-line analysis of protein compositions |
FI2914248T4 (fi) | 2012-11-02 | 2023-12-19 | Vertex Pharma | Farmaseuttisia koostumuksia cftr-välitteisten tautien hoitamiseksi |
US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
EP3131582B1 (en) | 2014-04-15 | 2018-05-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
CN107690281B (zh) | 2014-10-06 | 2020-11-17 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
WO2016057730A1 (en) | 2014-10-07 | 2016-04-14 | Strohmeier Mark | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
WO2016086136A1 (en) | 2014-11-26 | 2016-06-02 | Catabasis Pharmaceuticals, Inc. | Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders |
MA41031A (fr) | 2014-11-26 | 2017-10-03 | Catabasis Pharmaceuticals Inc | Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie |
CA2969587A1 (en) | 2014-12-05 | 2016-06-09 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating cystic fibrosis |
WO2016123028A1 (en) | 2015-01-26 | 2016-08-04 | Rigel Pharmaceuticals, Inc. | Tetrazolones as carboxylic acid bioisosteres |
UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
-
2014
- 2014-10-31 PT PT148625049T patent/PT3068392T/pt unknown
- 2014-10-31 BR BR112016010403A patent/BR112016010403A2/pt not_active Application Discontinuation
- 2014-10-31 CA CA2930199A patent/CA2930199C/en active Active
- 2014-10-31 SG SG10201803930QA patent/SG10201803930QA/en unknown
- 2014-10-31 EP EP14862504.9A patent/EP3068392B9/en active Active
- 2014-10-31 CN CN201480071195.7A patent/CN105848657B/zh active Active
- 2014-10-31 SI SI201431804T patent/SI3068392T1/sl unknown
- 2014-10-31 DK DK14862504.9T patent/DK3068392T5/da active
- 2014-10-31 PL PL14862504T patent/PL3068392T3/pl unknown
- 2014-10-31 KR KR1020167015564A patent/KR102280372B1/ko active IP Right Grant
- 2014-10-31 NZ NZ720958A patent/NZ720958A/en unknown
- 2014-10-31 RU RU2019107168A patent/RU2718044C2/ru active
- 2014-10-31 US US15/035,969 patent/US10231932B2/en active Active
- 2014-10-31 ES ES14862504T patent/ES2865600T3/es active Active
- 2014-10-31 JP JP2016553220A patent/JP6963896B2/ja active Active
- 2014-10-31 MX MX2016006118A patent/MX2016006118A/es unknown
- 2014-10-31 RU RU2016122882A patent/RU2016122882A/ru not_active Application Discontinuation
- 2014-10-31 AU AU2014349010A patent/AU2014349010C1/en active Active
- 2014-10-31 HU HUE14862504A patent/HUE054389T2/hu unknown
- 2014-10-31 WO PCT/US2014/063506 patent/WO2015073231A1/en active Application Filing
- 2014-10-31 RS RS20210500A patent/RS61790B1/sr unknown
-
2016
- 2016-05-10 IL IL245584A patent/IL245584A0/en unknown
- 2016-06-10 ZA ZA2016/03973A patent/ZA201603973B/en unknown
-
2020
- 2020-09-21 IL IL277470A patent/IL277470A/en unknown
-
2021
- 2021-03-30 HR HRP20210516TT patent/HRP20210516T2/hr unknown
- 2021-07-06 JP JP2021112157A patent/JP2021165300A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210516T2 (hr) | Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr | |
HRP20200046T1 (hr) | Formulacije apiksabana | |
NZ607118A (en) | C-met modulator pharmaceutical compositions | |
Srivastava et al. | Formulation and evaluation of Paracetamol tablets to assess binding property of orange peel pectin | |
JP2013521226A5 (hr) | ||
KR102465306B1 (ko) | 무첨가 한약재 파벽 분말 과립 제제의 제조 방법 | |
JP2008280268A (ja) | メコバラミン含有粉体 | |
CN105168243A (zh) | 一种儿童用复合碳酸钙及维生素d3咀嚼片及其制备方法 | |
Sood et al. | Understanding pharmaceutical polymorphic transformations I: Influence of process variables and storage conditions | |
US20170157098A1 (en) | Clopidogrel Hydrogen Sulfate Solid Preparation and Its Preparation Method | |
CN104000796A (zh) | 用于中药提取物制剂的包衣辅料、制备方法及包衣方法 | |
CN103417580B (zh) | 菲牛蛭中高活性抗凝剂粗品的制备方法 | |
CN110368367A (zh) | 盐酸多西环素片剂及其制备方法和应用、抗菌药物 | |
CN108743552A (zh) | 一种复方磺胺甲噁唑片剂及其制备方法 | |
CN102988372B (zh) | 复方阿司匹林片主要辅料的筛选和组成及其制备方法 | |
CN103494952A (zh) | 五子衍宗丸及其制备工艺 | |
CN109953960A (zh) | 一种苯磺酸氨氯地平片的制备方法 | |
Samanta et al. | Energy-based analysis of cone milling process for the comminution of roller compacted flakes | |
CN103070831A (zh) | 10~90%叶酸颗粒制备方法 | |
KR101462367B1 (ko) | 알코올이 포함되지 않은 홍삼 타브렛 | |
CN102921008B (zh) | 一种含有钙阻滞剂的药物组合物 | |
CN105498684A (zh) | 一种中空玻璃干燥剂 | |
CN103705482A (zh) | 一种硫普罗宁片的制备方法 | |
CN103142522B (zh) | 一种依托泊苷片剂 | |
CN103083276A (zh) | 一种快速崩解的维生素c泡腾片及其制备方法 |